Have a question or topic idea for The Life Science Report? Submit it here.
The Latest on Antibiotic Development with Antabio
Antibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments safer, but what happens when bacteria or other microorganisms become resistant to the drugs we use against them?
Marc Lemonnier, a molecular and cellular microbiologist and CEO of Antabio, a clinical-stage company located in France developing novel antibiotic therapies, joins Back Bay for a conversation on the current clinical landscape of novel agents to address antimicrobial resistance and the regional and global initiatives to tackle the issue.
Topics include:
The growing rates of antimicrobial resistance (AMR)
Which global organizations are at work on this issue and their list of priority pathogens
How COVID 19 and the pandemic exacerbated the issue of AMR
Push and pull incentives and subscription models for innovative antimicrobials and how they work in various countries around the world
Why global access is a real issue and how to solve the problem
For more, read Back Bay Life Science Advisors' recent take on the role of investments in antimicrobials in STAT here.
Subscribe:
Apple Podcasts | Libsyn | Spotify | Stitcher
